Penile carcinoma (PC) is a rare malignancy with substantial geographic and etiological heterogeneity. Histologically, it is stratified into HPV-associated and HPV-independent subtypes, each with distinct clinical behaviors and molecular features.
Prognostic markers such as histologic tumor stage, grade, nodal involvement, and lymphovascular invasion guide therapeutic decision-making, while emerging predictive biomarkers-HPV status, PD-L1 expression, and tumor mutational burden-show potential to personalize systemic treatment. Advances in tumor microenvironment (TME) profiling have revealed immune and stromal signatures that have the potential to influence treatment response. While immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) show early clinical benefits, biomarker-driven patient selection remains essential to optimize efficacy. This review summarizes current evidence on the TME in PC and novel therapeutic strategies, aiming to guide future personalized treatment strategies.
Urologic oncology. 2026 Feb 21 [Epub ahead of print]
August Fiegl, Jan Mink, Kerstin Junker, Arndt Hartmann, Markus Eckstein
Institute of Pathology, University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany. Electronic address: ., Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany., Institute of Pathology, University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/41724630